Get the Stockscreener App
15.10
0.13%
-0.02
After Hours:
15.10
Integra Lifesciences Holdings Corp stock is traded at $15.10, with a volume of 814.61K.
It is down -0.13% in the last 24 hours and up +40.47% over the past month.
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.
See More
Previous Close:
$15.12
Open:
$15.11
24h Volume:
814.61K
Relative Volume:
0.86
Market Cap:
$1.17B
Revenue:
$1.64B
Net Income/Loss:
$-495.80M
P/E Ratio:
-2.3579
EPS:
-6.404
Net Cash Flow:
$-45.25M
1W Performance:
+7.09%
1M Performance:
+40.47%
6M Performance:
+25.42%
1Y Performance:
+19.27%
1-Day Range:
$14.82
$15.38
1-Week Range:
$13.81
$15.45
52-Week Range:
$8.70
$16.49
Integra Lifesciences Holdings Corp Stock (IART) Company Profile
Name
Integra Lifesciences Holdings Corp
Sector
Industry
Phone
(609) 275-0500
Address
1100 CAMPUS ROAD, PRINCETON, NJ
Compare IART vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IART
Integra Lifesciences Holdings Corp
|
15.10 | 1.18B | 1.64B | -495.80M | -45.25M | -6.404 |
ABT
Abbott Laboratories
|
87.41 | 152.88B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
316.48 | 120.18B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.60 | 100.34B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.78 | 84.95B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.78 | 47.91B | 6.30B | 1.07B | 1.09B | 1.8406 |
Integra Lifesciences Holdings Corp Stock (IART) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Downgrade | Argus | Buy → Hold |
| Mar-31-25 | Upgrade | Argus | Hold → Buy |
| Dec-02-24 | Initiated | Morgan Stanley | Underweight |
| Oct-07-24 | Upgrade | BTIG Research | Sell → Neutral |
| Jul-30-24 | Downgrade | BTIG Research | Neutral → Sell |
| Jul-30-24 | Downgrade | Citigroup | Neutral → Sell |
| May-07-24 | Downgrade | Oppenheimer | Outperform → Perform |
| May-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-03-24 | Upgrade | Citigroup | Sell → Neutral |
| Dec-05-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-14-23 | Initiated | CL King | Buy |
| Aug-24-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-12-23 | Upgrade | Jefferies | Hold → Buy |
| Jun-08-23 | Downgrade | Argus | Buy → Hold |
| May-24-23 | Downgrade | JP Morgan | Neutral → Underweight |
| May-23-23 | Downgrade | Citigroup | Neutral → Sell |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-25-22 | Initiated | Morgan Stanley | Equal-Weight |
| Apr-13-22 | Downgrade | Truist | Buy → Hold |
| Dec-17-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-15-21 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-08-20 | Downgrade | JP Morgan | Neutral → Underweight |
| May-27-20 | Initiated | Citigroup | Neutral |
| Apr-03-20 | Initiated | SunTrust | Buy |
| Jan-07-20 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jan-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-03-19 | Initiated | SunTrust | Buy |
| Nov-28-18 | Initiated | UBS | Neutral |
| Aug-07-18 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jul-26-18 | Upgrade | BTIG Research | Neutral → Buy |
| Jul-02-18 | Downgrade | Citigroup | Buy → Neutral |
| Jan-05-18 | Resumed | Cantor Fitzgerald | Neutral |
| Jan-02-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Nov-09-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Oct-30-17 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Oct-27-17 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-30-17 | Initiated | Cantor Fitzgerald | Overweight |
| May-02-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jan-13-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jan-06-17 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Dec-12-16 | Initiated | UBS | Buy |
View All
Integra Lifesciences Holdings Corp Stock (IART) Latest News
Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It - Benzinga
Why Integra LifeSciences (IART) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Integra LifeSciences Says Transformation Is Working as SurgiMend Relaunch Nears - Yahoo Finance
Paradigm Capital holds 4.01M shares of Integra LifeSciences (IART) - Stock Titan
The Top 5 Analyst Questions From Integra LifeSciences’s Q1 Earnings Call - Yahoo Finance
Integra LifeSciences (IART) Is Up 6.4% After Essig Returns As CEO With Reaffirmed 2026 Guidance - Yahoo Finance
Integra (IART) director receives 24,338-share stock awards - Stock Titan
Integra (IART) director gets 17,700 RSUs; 882 shares withheld for taxes - Stock Titan
Integra LifeSciences (IART) director receives 17,700 RSU grant - Stock Titan
Integra LifeSciences (IART) director Jeffrey Graves receives 17,700 RSU award - Stock Titan
Renee Wonlai Lo awarded 17,700 RSUs at Integra LifeSciences (IART) - Stock Titan
Integra LifeSciences (IART) director awarded 17,700 deferred RSUs - Stock Titan
Earnings call transcript: Integra LifeSciences beats Q1 2026 expectations - Investing.com
Integra LifeSciences Leadership Shift And ESOP Move Highlight Valuation Gap - Yahoo Finance
Integra LifeSciences (NASDAQ: IART) expands equity plan and elects full board - Stock Titan
IART CLASS ACTION ALERT: Hagens Berman Encourages Integra LifeSciences (IART) Investors with Substantial Losses to Contact Firm’s Attorneys, Securities Fraud Lawsuit Pending - ACCESS Newswire
Integra LifeSciences to webcast May 12 BofA conference talk - Stock Titan
Integra LifeSciences to Present at the BofA Securities 2026 Health Care Conference - GlobeNewswire
Integra LifeSciences Holdings Corporation (NASDAQ:IART) Q1 2026 Earnings Call Transcript - Insider Monkey
symbol__ Stock Quote Price and Forecast - CNN
Integra LifeSciences Holdings Corporation Q1 2026 Earnings Call Summary - Yahoo Finance
Integra LifeSciences Holdings Corporation (IART) Releases Q1 2026 Earnings: Revenue Up but EPS Miss - Quiver Quantitative
Revenue and net loss details for Integra LifeSciences (NASDAQ: IART) Q1 2026 - Stock Titan
Integra LifeSciences Q1 Earnings Call Highlights - Yahoo Finance
Rockwell Automation Posts Upbeat Q2 Results, Joins EverQuote, DigitalOcean And Other Big Stocks Moving Hi - Benzinga
Earnings call transcript: Integra LifeSciences Q1 2026 results beat forecasts, stock surges - Investing.com
Integra Lifesciences Holdings Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Q1 2026 Integra Lifesciences Holdings Corp Earnings Call Transcript - GuruFocus
MSN Money - MSN
Integra LifeSciences (IART) Beats Q1 Earnings and Revenue Estimates - Yahoo! Finance Canada
Integra LifeSciences : Q1’2026 Earnings Call - marketscreener.com
Stuart Essig returns as Integra LifeSciences (NASDAQ: IART) CEO - Stock Titan
Integra: Q1 Earnings Snapshot - marketscreener.com
Integra LifeSciences (NASDAQ: IART) boosts 2026 adjusted EPS outlook - Stock Titan
Integra raises 2026 profit outlook; Integra Skin posts double-digit growth - Stock Titan
Integra LifeSciences (NASDAQ:IART) Exceeds Q1 CY2026 Expectations - Yahoo Finance
Integra LifeSciences Announces Leadership Transition - GlobeNewswire
What To Expect From Integra LifeSciences’s (IART) Q1 Earnings - Yahoo Finance
Integra LifeSciences (IART) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo Finance
Integra LifeSciences (IART) to Release Earnings on Tuesday - MarketBeat
RS Investment Management's Integra Lifesciences Holdings Corp(IART) Holding History - GuruFocus
IART Price Today: Integra LifeSciences Holdings Stock Price, Quote & Chart | MEXC - MEXC Exchange
Here's Why Integra LifeSciences (IART) is a Strong Momentum Stock - Yahoo Finance
Integra Lifesciences Holdings (STU:IL3) Cash Payments for L - GuruFocus
INTEGRA SHAREHOLDER ALERT: Kaskela Law Firm Announces Shareholder Investigation of ... - Bluefield Daily Telegraph
INTEGRA SHAREHOLDER ALERT: Kaskela Law Firm Announces - GlobeNewswire
Integra LifeSciences posts Q1 results May 5 before market open - Stock Titan
Integra LifeSciences (IART): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance
Why Integra (IART) is Poised to Beat Earnings Estimates Again - Yahoo Finance
Integra LifeSciences Holdings Corp Files Form 8-K Announcing Material Definitive Agreement (April 10, 2026) - Minichart
Integra LifeSciences (NASDAQ: IART) extends $150M receivables facility to 2029 - Stock Titan
Integra Lifesciences Holdings Corp Stock (IART) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.22%
1.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):